US mRNA specialist biotech Moderna (Nasdaq: MRNA) today reported financial results for the fourth quarter and fiscal year 2022 that disappointed and sent its shares down 7.5% at $146.63 in mid-morning in trading.
Total revenue for the fourth quarter of 2022 was $5.1 billion, down almost 30% compared to $7.2 billion in the same period in 2021, mainly due to a decrease in sales of the company's COVID-19 vaccines. However, this was in line with analyst expectations of $5.0 billion.
Net income decreased by 70% to $1.5 billion in the fourth quarter of 2022. Diluted earnings per share (EPS) plunged 68% to $3.61 in the fourth quarter of 2022, and well below analysts’ expectations of $4.68.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze